Research Reports
Medgenome Unlisted Shares
Medgenome company logo

Medgenome Share Price

DMAT
PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX
High

₹2,328

Low

₹2

Return

-

Medgenome Essentials

As of April 08, 2026, Medgenome Labs, Unlisted Shares are trading at ₹2,328.00 per share and face value is ₹10.00/share, with a 52-week high of ₹2,328.00 and 52-week low of ₹2,328.00. The minimun lot size is None shares, and the shares are traded on .
ISIN
info icon
INE00K701014
Face Value
info icon
10
Total Shares
info icon
24,88,893
Market Cap
info icon
579.41 Cr
Sector
info icon
Health Care
Sub-sector
info icon
Hospitals & Diagnostics Centres
Category
info icon
Soonicorn

About Medgenome

Company Overview:

  • MedGenomeis a global leader in Genetic Testing services, Genomics Research, and drug discovery solutions. It operates a multi-pronged business model that capitalizes on the growing demand for personalized medicine and genetic insights.
  • MedGenome has been committed to delivering world-class genomic solutions with greater precision and accuracy to empower every human being for better management of their health since 2013. MedGenome utilizes advanced technologies like Next-Generation Sequencing (NGS) for in-depth genetic analysis, aiding in complex diagnosis and personalized treatment plans. 
  • MedGenome is the only CAP-accredited Genetic testing lab in India that offers 1300+ genetic tests backed by the best and the latest testing technologies available across the world. MedGenome is dedicated to bringing the best precision testing solutions for quicker and smarter diagnosis of complex diseases. It operates the largest College of American Pathologists (CAP) accredited Next-Generation Sequencing (NGS) lab in South East Asia housing cutting-edge genome sequencing platforms such as Illumina's NovaSeq, HiSeq X, MiSeq, etc.
  • MedGenome actively engages in research and development services, partnering with pharmaceutical companies and research institutions. This segment offers various services like collaborating on projects related to drug discovery, pharmacogenomics, and biomarker development; storing and managing biological samples for future research endeavors; and providing expertise and infrastructure to conduct genomics and personalized medicine trials.
  • MedGenome recognized the value of strategic partnerships and collaboration with various entities including hospitals and clinics which expands their market reach and allows them to offer comprehensive care solutions to patients; pharmaceutical and research institutions which facilitate joint research projects, drug development initiatives, and clinical trials, accelerating advanced in the filed; technology companies which allow MedGenome to develop innovative solutions for data analysis, genetic testing, and personalized medicine applications.
  • MedGenome Labs Limited was incorporated on 8 April 2013, with its registered office at No. 258/A,3rd Floor Narayana Nethralaya, Narayana Health City, Hosur Road, Bommasandra Bangalore Bangalore KA 560099 IN.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Medgenome Media

News
Articles
Videos
‘Geographical expansions, augmented investments for new solutions to remain key focal areas for MedGenome’
‘Geographical expansions, augmented investments for new solutions to remain key focal areas for MedGenome’
07 Oct 2023
Financial Express
MedGenome acquires Illumina’s NovaSeq X Plus; launches Genome Sequencing Test
MedGenome acquires Illumina’s NovaSeq X Plus; launches Genome Sequencing Test
09 Jul 2023
Financial Express
MedGenome, backed by Sequoia Capital, acquires Delhi-NCR based Prognosis Laboratories
MedGenome, backed by Sequoia Capital, acquires Delhi-NCR based Prognosis Laboratories
25 May 2023
The Economic Times

Medgenome

₹ 2,328

cartIcon